al7bebe
عضو نشط
- التسجيل
- 24 مارس 2005
- المشاركات
- 10,052
If BZH falters today: this one gained 59% in a week 22-Jul-08 11:04 pm Hello BZH; Take a look at this promising new biotech, CCYG, which gained 59% in the past week. This just in - CCYG has retained the crack investment banking firm InCap Group:
CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing
BOTHELL, Wash., PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: CCYG - News) has engaged InCap Group, Inc. (InCap) to provide strategic investment and financial advice and services. CellCyte seeks to build shareholder value by monetizing its two core platform technologies and will work with InCap to initiate a corporate partnering strategy to exploit development and commercialization of CellCyte's cell expander and stem cell delivery technologies.
"We are committed to realizing the value in our two stem cell enabling technologies and look forward to the counsel InCap can provide in this regard as well as their assistance in executing staged capital raises," said Gary A. Reys, President and CEO of CellCyte.
"The promise of stem cells in regenerative medicine has been hampered by the inability to generate sufficient cells and the lack of effective non-invasive ways to deliver them to the therapeutic target. CellCyte's two technology platforms may provide the solutions to both of these fundamental problems. We are excited about helping the Company commercialize its highly leveraged technologies," noted Paul J. Marangos, Ph.D., a consultant with InCap.
"CellCyte's strategic initiatives include:
-- Transitioning from a research to a commercialization business approach
-- Establishing a partnering strategy targeting multiple companies involved in the clinical exploitation of stem cells
-- Accelerating the development and commercialization of the company's cell expander bioreactor technology
-- Staged milestone driven capital formation
"About InCap Group
"InCap Group, Inc., is an investment banking firm focused on the investment management and securities brokerage industries. They provide merger and acquisition services, capital raising services, valuations and strategic advice to their clients. The professionals at InCap were deeply involved in many of Legg Mason, Inc.'s investment management acquisitions, which resulted in the firm being transformed from a modest regional securities brokerage firm to one of the ten largest asset management firms in the world. InCap's professionals have worked at other leading industry firms including Fidelity Investments, SEI Investments, PaineWebber, and Oppenheimer & Co.
"About CellCyte Genetics
"CellCyte Genetics is a biotechnology company engaged in the discovery, development and commercialization of stem cell enabling therapeutic products. CellCyte is developing products to allow more efficient delivery and increased retention of adult stem cells to diseased organs, such as the heart. The goal of these therapies is to increase the number of stem cells delivered to a damaged organ, thereby markedly increasing organ healing and functional restoration. The Company's lead product, CCG-TH30, is being developed to send autologous bone marrow-derived (adult) stem cells to the heart of patients after a heaLast Trade: 5.51
Trade Time: 2:38PM ET
Change: 0.77 (16.24%)
Prev Close: 4.74
Open: 4.84
Bid: N/A
Ask: N/A
1y Target Est: 7.00
Day's Range: 4.76 - 5.56
52wk Range: 3.36 - 18.42
Volume: 1,181,241
Avg Vol (3m): 1,832,270
Market Cap: 216.18M
P/E (ttm): N/A
EPS (ttm): -16.68
rt attack.
CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing
BOTHELL, Wash., PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: CCYG - News) has engaged InCap Group, Inc. (InCap) to provide strategic investment and financial advice and services. CellCyte seeks to build shareholder value by monetizing its two core platform technologies and will work with InCap to initiate a corporate partnering strategy to exploit development and commercialization of CellCyte's cell expander and stem cell delivery technologies.
"We are committed to realizing the value in our two stem cell enabling technologies and look forward to the counsel InCap can provide in this regard as well as their assistance in executing staged capital raises," said Gary A. Reys, President and CEO of CellCyte.
"The promise of stem cells in regenerative medicine has been hampered by the inability to generate sufficient cells and the lack of effective non-invasive ways to deliver them to the therapeutic target. CellCyte's two technology platforms may provide the solutions to both of these fundamental problems. We are excited about helping the Company commercialize its highly leveraged technologies," noted Paul J. Marangos, Ph.D., a consultant with InCap.
"CellCyte's strategic initiatives include:
-- Transitioning from a research to a commercialization business approach
-- Establishing a partnering strategy targeting multiple companies involved in the clinical exploitation of stem cells
-- Accelerating the development and commercialization of the company's cell expander bioreactor technology
-- Staged milestone driven capital formation
"About InCap Group
"InCap Group, Inc., is an investment banking firm focused on the investment management and securities brokerage industries. They provide merger and acquisition services, capital raising services, valuations and strategic advice to their clients. The professionals at InCap were deeply involved in many of Legg Mason, Inc.'s investment management acquisitions, which resulted in the firm being transformed from a modest regional securities brokerage firm to one of the ten largest asset management firms in the world. InCap's professionals have worked at other leading industry firms including Fidelity Investments, SEI Investments, PaineWebber, and Oppenheimer & Co.
"About CellCyte Genetics
"CellCyte Genetics is a biotechnology company engaged in the discovery, development and commercialization of stem cell enabling therapeutic products. CellCyte is developing products to allow more efficient delivery and increased retention of adult stem cells to diseased organs, such as the heart. The goal of these therapies is to increase the number of stem cells delivered to a damaged organ, thereby markedly increasing organ healing and functional restoration. The Company's lead product, CCG-TH30, is being developed to send autologous bone marrow-derived (adult) stem cells to the heart of patients after a heaLast Trade: 5.51
Trade Time: 2:38PM ET
Change: 0.77 (16.24%)
Prev Close: 4.74
Open: 4.84
Bid: N/A
Ask: N/A
1y Target Est: 7.00
Day's Range: 4.76 - 5.56
52wk Range: 3.36 - 18.42
Volume: 1,181,241
Avg Vol (3m): 1,832,270
Market Cap: 216.18M
P/E (ttm): N/A
EPS (ttm): -16.68
rt attack.
